SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunoGen
IMGN 31.230.0%Feb 26 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RJMC who wrote (3792)12/31/2000 4:07:29 PM
From: Sea Otter  Read Replies (1) of 5665
 
CEA

Per Mitch's statement that declining CEA correlates
with clinical response, and that we are seeing
declining levels. This appears to be the key
claim.

oncolink.upenn.edu

Of course we don't know how much CEA levels
declined in the trial. Even so, Mitch doesn't appear
to be blowing smoke. Per this link, declining
CEA levels are indeed a critical and accepted marker for
therapy success. For instance, 94-96% specificity
in detecting liver metastases!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News